TipRanks on MSN

Incyte’s INCA33890: A Promising Step in Cancer Treatment

Incyte (($INCY)) announced an update on their ongoing clinical study. Incyte Corporation is currently conducting a Phase 1 clinical study titled A ...
TipRanks on MSN

Merus to present interim data on petosemtamab at AACR-NCI-EORTC conference

Merus (MRUS) announced interim clinical data as of a July 29, 2025 data cutoff from the ongoing phase 2 trial of the bispecific antibody ...

Merus’ Interim Data on Petosemtamab in Metastatic Colorectal Cancer Demonstrates Monotherapy Activity and Robust Response Rate in Combination with FOLFOX/FOLFIRI with Well ...

L left-sided mCRC (n=8, confirmed and unconfirmed) – 62% response rate in 2L left- and right-sided mCRC (n=13, confirmed and unconfirmed) UTRECHT, The Netherlands and CAMBRIDGE, Mass., Oct. 24, 2025 ...